analytical characterisation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-27. Anything still debated is marked as such rather than presented as settled.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Mouse lipoxygenases) are resistant to a) streptozotocin-induced, b) high fat diet-induced, and c) autoimmune-induced diabetes. Further studies in animal models suggest that the 12S-HETE made by pancreatic beta cells (or possibly alpha cells or other cell types indigenous to or invading the pancreatic islands) orchestrate a local immune response that results in the injury and, when extreme, death of beta cells. These results suggest that the 12-lipoxygenase-12S-HETE pathway is one factor contributing to immunity-based type I diabetes as well as low insulin output type II diabetes.
This effect is less pronounced at room temperature, due to annihilation of radiation defects; also heating to room temperature the sample which was kept for hours at low temperatures restores its resistivity. In fresh samples, the resistivity gradually increases with temperature from about 2 μOhm·cm at liquid helium to 69 μOhm·cm at room temperature; this behavior is similar to that of neptunium, uranium, thorium and protactinium, but is different from plutonium and curium which show a rapid rise up to 60 K followed by saturation. The room temperature value for americium is lower than that of neptunium, plutonium and curium, but higher than for uranium, thorium and protactinium. Americium is paramagnetic in a wide temperature range, from that of liquid helium, to room temperature and above. This behavior is markedly different from that of its neighbor curium which exhibits antiferromagnetic transition at 52 K. The thermal expansion coefficient of americium is slightly anisotropic and amounts to (7.5±0.2)×10−6 /°C along the shorter a axis and (6.2±0.4)×10−6 /°C for the longer c hexagonal axis. The enthalpy of dissolution of americium metal in hydrochloric acid at standard conditions is −620.6±1.3 kJ/mol, from which the standard enthalpy change of formation (ΔfH°) of aqueous Am3+ ion is −621.2±2.0 kJ/mol. The standard potential Am3+/Am0 is −2.08±0.01 V.
== Interactions == Nonsteroidal anti-inflammatory drugs (such as salicylates), sulfonamides, chloramphenicol, warfarin and probenecid may potentiate the hypoglycemic action of glimepiride. Thiazides, other diuretics, phothiazides, thyroid products, oral contraceptives, and phenytoin tend to produce hyperglycemia.
Sources: en.wikipedia.org
Nevertheless, Essendon went on to win the 1942 Premiership with Western Australian Wally Buttsworth in irrepressible form at centre half-back. Essendon won the 1942 Premiership by defeating Richmond in the grand final, 19.18 (132) to 11.13 (79). The match was played at Princes Park in front of 49,000 spectators. Essendon lost the 1943 grand final to Richmond by 5 points, finished 3rd in 1944, and dropped to 8th in 1945. After World War II, Essendon enjoyed great success. In the five years immediately after the war, Essendon won three premierships (1946, 1949, 1950) and were runners-up twice (1947, 1948). In 1946, Essendon were clearly the VFL's supreme force, topping the ladder after the home-and-away games and surviving a drawn second semi-final against Collingwood to make it through to the grand final a week later with a score of 10.16 (76) to 8.9 (57). In the grand final against Melbourne, Essendon set a grand final record score of 22.18 (150) to Melbourne 13.9 (87), featuring a 7-goal performance by centre half-forward Gordon Lane. Rover Bill Hutchinson, and defenders Wally Buttsworth, Cec Ruddell and Harold Lambert were among the best players. Essendon lost the 1947 Grand Final to Carlton by a single point despite recording 30 scoring shots to 21. The following year, Essendon tied with Melbourne in the 1948 grand final, kicking 7.27 to Melbourne's 10.9, before losing the replay 13.11 (89) to 7.8 (50).
It is impossible to suppress the demand for drugs." He quoted Helen Clark, former prime minister of New Zealand and head of the Global Commission on Drug Policy: "The total elimination of drugs? Dream on, there's never been a time in human history where human beings haven't resorted to some kind of substances that will take them out of their current reality for whatever reason."
If, in the very intense electric field in the neighbourhood of the cathode, the molecules of the gas are dissociated and are split up, not into the ordinary chemical atoms, but into these primordial atoms, which we shall for brevity call corpuscles; and if these corpuscles are charged with electricity and projected from the cathode by the electric field, they would behave exactly like the cathode rays. Thomson imagined the atom as being made up of these corpuscles orbiting in a sea of positive charge; this was his plum pudding model. This model was later proved incorrect when his student Ernest Rutherford showed that the positive charge is concentrated in the nucleus of the atom.
Sources: en.wikipedia.org
One way to bypass these issues is the use of droplets to compartmentalize separation bands, which combats diffusion and the loss of separated analytes. In early attempts to integrate chromatography with droplet microfluidics, the lower flow rates and pressures required for 2-D capillary LC provided less of an obstacle to overcome in combining these technologies and made it possible to couple multiple 2-D separation techniques into one device (i.e. HPLC x LC, LC x LC, and HPLC x HPLC). HPLC autosamplers feeding into microfluidic devices have taken advantage of the dispersion occurring between separation and droplet formation to feed gradient pulses of analytes into microfluidic devices where the production of thousands of pico-liter droplets captures unique analyte concentrations. Similar approaches have used the withdrawal capabilities of a syringe pump to align the relatively high flow rates necessary for HPLC with the lower flow rates of the continuous medium common in microfluidic devices. The development of nano-LC, or nano-UPLC, has provided another opportunity for coupling with microfluidic devices such that large droplet libraries can be formed with multiple dimensions of information being stored in each droplet. Instead of identifying peaks and storing them as a single sample, as seen in standard LC, these droplet libraries allow for the specific concentration of the analyte to be retained along with its identity.
The reinforcing effects of alcohol consumption are mediated by acetaldehyde generated by catalase and other oxidizing enzymes such as cytochrome P-4502E1 in the brain. Although acetaldehyde has been associated with some of the adverse and toxic effects of ethanol, it appears to play a central role in the activation of the mesolimbic dopamine system. Ethanol's rewarding and reinforcing (i.e., addictive) properties are mediated through its effects on dopamine neurons in the mesolimbic reward pathway, which connects the ventral tegmental area to the nucleus accumbens (NAcc). One of ethanol's primary effects is the allosteric inhibition of NMDA receptors and facilitation of GABAA receptors (e.g., enhanced GABAA receptor-mediated chloride flux through allosteric regulation of the receptor). At high doses, ethanol inhibits most ligand-gated ion channels and voltage-gated ion channels in neurons as well. With acute alcohol consumption, dopamine is released in the synapses of the mesolimbic pathway, in turn heightening activation of postsynaptic D1 receptors. The activation of these receptors triggers postsynaptic internal signaling events through protein kinase A, which ultimately phosphorylate cAMP response element binding protein (CREB), inducing CREB-mediated changes in gene expression. With chronic alcohol intake, consumption of ethanol similarly induces CREB phosphorylation through the D1 receptor pathway, but it also alters NMDA receptor function through phosphorylation mechanisms; an adaptive downregulation of the D1 receptor pathway and CREB function occurs as well.
=== 18 January === Forty people were killed in an RSF attack on the village of Jebel Hilla in North Darfur. Six drones struck the Al-Shawak power station in Gedaref State, injuring civil defence personnel and causing blackouts across the state and in Kassala State. Other drones hit the Gedaref state water station while another crashed near a bus station along the Gedaref-Kassala-Port Sudan highway. The SAF reached the Al-Shukri junction in Shambat, Khartoum Bahri, while the RSF retreated by one kilometer southwards to the Hassan Ibrahim Malik University City. At least three people were killed by RSF shelling in Omdurman. The RSF claimed to have taken Al-Hallaf, Drishaqi and Mao in North Darfur.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.